OCT 30, 2014 07:30 AM PDT

Challenges in biomarker testing in non-small cell lung cancer research

Speakers
  • Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
    Biography
      Dr. Normanno earned his Medical Doctor Degree in 1988 at the Medical School of the University of Naples (Italy) Federico II. He received his spacialization in Medical Oncology in 1991, and in Hematology in 2001, at the same university. Between 1990 and 1993, Dr. Normanno completed a postoctoral fellowship studying tumor growth factors at the National Institutes of Health, Bethesda, MD. Since 1993, Dr. Normanno's areas of research have been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; and identification of markers of response or resistance to anti EGFR agents. Dr. Normanno is a member of the American Association for Cancer Research, the Italian Tumor Society, and the Italian Cancer Society. He is the author of over 140 papers published in peer reviewed journals. After serving as Senior Investigator, and later, Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same Hospital, and since 2006, is also Director of the Research Department.

    Abstract:

    Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved drugs. More than 1500 fusion transcripts have been published to date, but current practices for fusion transcript detection are hampered by high cost and bias. Typically only the top 1-2 commonly observed fusion transcripts are characterized for most samples.

    We have developed a next-generation sequencing solution for highly multiplexed fusion transcript analysis. Using this workflow, hundreds of fusion transcripts can be simultaneously tested in fewer than 24 hours.

    In this presentation, Dr Normanno will present an Ion AmpliSeqTM method for fusion detection and analysis from non-small cell lung cancer research samples.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    Loading Comments...
    Show Resources